OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.

Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.

What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?

To have a presence in the entire US HA market, OrthogenRx aims to provide...

Frederique Buntoum (aka Freddy), SmartTRAK's Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules, will be representing SmartTRAK at TOBI 2019, the Tenth Annual PRP & Regenerative Medicine Symposium in Chicago, IL, June 6-8. 

You can view Freddy's intro video below...

Frederique Buntoum (aka Freddy) has joined BioMedGPS as Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules. Formerly Senior Manager of Market Insights at Bioventus, Freddy has broad experience in sales, marketing and competitive intelligence. Her passion for market research and uncovering the “why” behind industry developments complements SmartTRAK’s team of domain experts and her thoughtful and keen insights and out-of-the-box perspective on market happenings make her a great addition to the SmartTRAK analyst team.

In addition to her role as an analyst, Freddy will also be assisting with consulting projects and product development initiatives – two key areas that will contribute to BioMedGPS growth in 2019.

Freddy will be representing SmartTRAK at the upcoming AAOS meeting. Please Contact us if you would like to set up a time to meet.

The US Surgical Matrices Market continued to advance in Q318, up +10.3% YoY, fueled by continued rapid adoption of allograft breast matrices and the resurgence of synthetic hernia matrices.

According to BioMedGPS’ SmartTRAK Financial Dashboard, in Q318, the US Surgical Matrices Market grew +10.3% YoY. The allograft breast matrices and biosynthetic hernia matrices segments outpaced overall market growth, as both posted...

Among the many interesting topics covered in the Q318 US Surgical Matrices Market Recap are:

The SmartTRAK analyst team is expanding and we are looking for an experienced and motivated individual who would like to manage one or more of our Regenerative Medicine modules. As you know, all of our SmartTRAK analysts are former marketing, business development or competitive intelligence professionals with one of the major medical device manufacturers and, in fact, most have come to us via recommendations from our subscribers. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add to the SmartTRAK platform.
 
We are specifically interested in a person who wants to work 15-20 hours per week with experience in one or more of the following subject areas:

BioMedGPS, the leader in online business intelligence for the Medical Device and Life Science industries, is seeking a Regenerative Medicine Analyst to support SmartTRAK Business Intelligence, an online, comprehensive, easy-to-use, web-based business intelligence solution used by the top 10 orthopedic implant companies and top 15 global wound care manufacturers. SmartTRAK integrates real time market data and analysis accessible throughout an organization, fostering an innovative collaborative approach to market strategy resulting in better decision-making.

We are looking for an experienced, motivated individual with expertise in the Regenerative Medicine market, with knowledge in one or more of the following areas:

SmartTRAK is excited to be attending TOBI 2018 - The 9th Annual PRP & Regenerative Medicine Symposium, Workshops & Cadaver Labs - June 7-9 at Wynn, Las Vegas, Nevada.

Regenerative medicines, the new era of human health, represent a wave of innovation coming to our health care system, approaching much faster than most realize. As of Q217, there were more than 822 companies developing regenerative medicine technologies.